At Living Well Wellness we understand the struggles of those with Opioid Addiction and we are committed to their growth by offering Suboxone and Subutex opioid addiction treatments through our certified Suboxone doctors at either our Daytona Beach or Casselberry, Florida location.
The opioid addiction program is overseen by our board certified Suboxone doctor and the program happens in 3 phases:
1. The Induction Phase is the medically monitored startup of buprenorphine treatment performed in a qualified physician’s office or certified opioid treatment program (OTP) using approved buprenorphine products. The medication is administered when a person with an opioid dependency has abstained from using opioids for 12 to 24 hours and is in the early stages of opioid withdrawal. It is important to note that buprenorphine can bring on acute withdrawal for patents who are not in the early stages of withdrawal and who have other opioids in their bloodstream.
2. The Stabilization Phase begins after a patient has discontinued or greatly reduced their misuse of the problem drug, no longer has cravings, and experiences few, if any, side effects. The buprenorphine dose may need to be adjusted during this phase. Because of the long-acting agent of buprenorphine, once patients have been stabilized, they can sometimes switch to alternate-day dosing instead of dosing every day.
3. The Maintenance Phase occurs when a patient is doing well on a steady dose of buprenorphine. The length of time of the maintenance phase is tailored to each patient and could be indefinite. People can engage in further treatment—with or without medication-assisted treatment (MAT)—to prevent a possible relapse.
It is also important to note that treatment of opioid dependency with buprenorphine is most effective in combination with counseling services, which can include different forms of behavioral therapy and self-help programs.
To help you understand our opioid addiction program, let’s break down what Suboxone actually is
Suboxone is the brand name for a prescription medication used in treating those addicted to opioids, whether illegal or prescription opioids. It contains the ingredients buprenorphine and naloxone. Buprenorphine, a partial opioid agonist, blocks the opiate receptors in the brain, and reduces a person’s urges. The second ingredient, naloxone, helps reverse the effects of opioids. Together, these drugs work to prevent withdrawal symptoms associated with an opioid addiction.
One common question we often get is: can I switch from my current Methadone treatment to buprenorphine?
Patients can possibly switch from Methadone to buprenorphine treatment, but because the two medications are so different, patients may not always be satisfied with the results. Studies indicate that buprenorphine is equally as effective as moderate doses of Methadone. However, because buprenorphine is unlikely to be as effective as more optimal-dose Methadone, it may not be the treatment of choice for patients with high levels of physical dependency.
A number of factors affect whether buprenorphine is a good choice for someone who is currently receiving Methadone. Patients receiving buprenorphine can possibly be switched to Methadone. Patients interested in learning more about switching their treatment should discuss this with their doctor.
Discrete appointments available!
For those looking for more privacy, at an additional cost we can book you a discrete appointment where you will be brought in through our back entrance and see the doctor directly.
Please call/text to book your discrete appointment
Other important information in regards to Buprenorphine, the main ingredient in suboxone and subutex:
Buprenorphine is used in medication-assisted treatment (MAT) to treat Opioid Use Disorder (OUD).
Approved for clinical use in October 2002 by the Food and Drug Administration (FDA), medications such as buprenorphine, in combination with counseling and behavioral therapies, provide a whole-patient approach to the treatment of opioid dependency. When taken as prescribed, buprenorphine is safe and effective.
Unlike methadone treatment, which must be performed in a highly structured clinic, buprenorphine is the first medication to treat opioid dependency that is permitted to be prescribed or dispensed in physician offices, significantly increasing treatment access. Under the Drug Addiction Treatment Act of 2000 (DATA 2000), qualified U.S. physicians, and mid-level practitioners with an X-license can offer buprenorphine for opioid dependency in various settings, including in an office (physicians only), community hospital, health department, or correctional facility (mid-level practitioners). Learn more about SAMHSA’s buprenorphine waiver management.
SAMHSA-certified opioid treatment programs (OTPs) also are allowed to offer buprenorphine, but only are permitted to dispense treatment. Learn more about certification of OTPs.
As with all medications used in MAT, buprenorphine is prescribed as part of a comprehensive treatment plan that includes counseling and participation in social support programs.
Buprenorphine offers several benefits to those with opioid dependency and to others for whom treatment in a methadone clinic is not preferred or is less convenient. The FDA has approved the following buprenorphine products:
Bunavail (buprenorphine and naloxone) buccal film
Suboxone (buprenorphine and naloxone) film
Zubsolv (buprenorphine and naloxone) sublingual tablets
Buprenorphine-containing transmucosal products for opioid dependency
Refer to the product websites for a complete listing of drug interactions, warnings, and precautions.
How Buprenorphine Works
Buprenorphine has unique pharmacological properties that help:
Lower the potential for misuse
Diminish the effects of physical dependency to opioids, such as withdrawal symptoms and cravings
Increase safety in cases of overdose
Buprenorphine is an opioid partial agonist. This means that, like opioids, it produces effects such as euphoria or respiratory depression at low to moderate doses. With buprenorphine, however, these effects are weaker than full opioid agonists such as heroin and methadone.
Buprenorphine’s opioid effects increase with each dose until at moderate doses they level off, even with further dose increases. This “ceiling effect” lowers the risk of misuse, dependency, and side effects. Also, because of buprenorphine’s long-acting agent, many patients may not have to take it every day.
Side Effects of Buprenorphine
Buprenorphine’s side effects are similar to those of opioids and can include:
Nausea, vomiting, and constipation
Muscle aches and cramps
Inability to sleep
Distress and irritability
Buprenorphine Misuse Potential
Because of buprenorphine’s opioid effects, it can be misused, particularly by people who do not have an opioid dependency. Naloxone is added to buprenorphine to decrease the likelihood of diversion and misuse of the combination drug product. When buprenorphine/naloxone is taken as a sublingual tablet, buprenorphine’s opioid effects dominate and mitigates opioid withdrawals. If the sublingual tablets are crushed and injected, the naloxone effect dominates and can block the euphoric effect and potentially bring on opioid withdrawal symptoms.
People should use the following precautions when taking buprenorphine:
Do not take other medications without first consulting your doctor.
Do not use illegal drugs, drink alcohol, or take sedatives, tranquilizers, or other drugs that slow breathing. Mixing large amounts of other medications with buprenorphine can lead to overdose or death.
Do ensure that a physician monitors any liver-related health issues that you may have.
Pregnant or Breastfeeding Women and Buprenorphine
Buprenorphine may be prescribed to women who are pregnant and have an opioid use disorder. Buprenorphine and methadone are considered the treatments of choice for OUD in pregnant and breastfeeding women.
Review SAMHSA’s Federal Guidelines for Opioid Treatment Programs – 2015 for more information about the use of buprenorphine in pregnancy. In the United States, methadone remains the current standard of care for the use of MAT with pregnant women who have opioid dependency.
Treatment with Buprenorphine
The ideal candidates for opioid dependency treatment with buprenorphine:
Have been objectively diagnosed with an opioid dependency
Are willing to follow safety precautions for the treatment
Have been cleared of any health conflicts with using buprenorphine
Have reviewed other treatment options before agreeing to buprenorphine treatment
Before buprenorphine treatment begins, policies and procedures should be in place to guarantee patient privacy and the confidentiality of personally identifiable health information. Under the Confidentiality Regulation, 42 Code of Federal Regulations (CFR) 2, information relating to substance use and alcohol treatment must be handled with a higher degree of confidentiality than other medical information.